^
Association details:
| Biomarker: | IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation |
|---|---|
| Cancer: | Anaplastic Astrocytoma |
| Drug: | carboplatin (Tubulin polymerization promoter) + temozolomide (DNA synthesis inhibitor) + vincristine (Tubulin polymerization inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature
Published date:
05/07/2021
Excerpt:
...Patient #1 had a noncanonical IDH1 R132S mutation by next‐generation sequencing....loss of immunoexpression of H3K27me3...Other genetic alterations identified included MET exon 14 skipping...Histopathology and molecular analysis led to an integrated diagnosis of anaplastic astrocytoma...she was treated with carboplatin, vincristine, and TMZ...progressed on treatment and died 62 months after initial diagnosis.
DOI:
https://doi.org/10.1111/bpa.12959
